Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:28 2024-04-19 pm EDT			After market 06:44:52 pm
726.3 ^USD	-2.63%		723.9	-0.34%

Apr. 18	India's Biocon developing its own version of Wegovy, clinical trial likely next year	RE
Apr. 17	Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	MT

Eli Lilly and : to cut 250 jobs at France plant, through voluntary redundancy

January 08, 2019 at 11:02 am EST

PARIS (Reuters) - Pharmaceutical group Eli Lilly said on Tuesday it will cut 250 jobs at its factory located near Strasbourg in Eastern France.

The company said it will reduce its payroll at the plant through a voluntary redundancy plan.

Eli Lilly currently employs 1,400 workers at the plant.

(Reporting by Gilbert Reilhac and Inti Landauro)

Latest news about Eli Lilly and Company

India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	Apr. 17	MT
Jefferies Raises Eli Lilly's Price Target to $895 From $885, Buy Rating Kept	Apr. 17	MT
Trending : Eli Lilly Weight-Loss Drug Works on Sleep Apnea	Apr. 17	DJ
Swiss Stocks Jump as Earnings Bonanza Begins; Luxury Stocks Shine on LVMH Boost	Apr. 17	MT
Wall St slips as dour earnings, chip stocks weigh	Apr. 17	RE
Global markets live: LVMH, ASML, Rio Tinto, Eli Lilly, Tesla...	Apr. 17
Eli Lilly's Weight-loss Drug Improves Sleep Apnea Symptoms in Late-stage Studies	Apr. 17	MT
Sector Update: Health Care Stocks Advance Premarket Wednesday	Apr. 17	MT
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says	Apr. 17	RE
The market is pinning its hopes on earnings reports	Apr. 17
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
Eli Lilly's Phase 3 Trials of Tirzepatide to Treat Sleep Apnea Meet Endpoints	Apr. 17	MT
Eli Lilly: positive data in sleep apnea	Apr. 17	CF
Studies Show Eli Lilly Weight-Loss Drug Helps With Sleep Apnea	Apr. 17	DJ
Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients	Apr. 17	RE
Eli Lilly and Company Announces Positive Topline Results of the Surmount-OSA Phase 3 Clinical Trials	Apr. 17	CI
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	Apr. 16	MT
Precision BioSciences to Regain Programs After Prevail Team-Up Ends	Apr. 16	DJ
Market sentiment sours	Apr. 16
Eli Lilly's $14 Million Insulin Settlement Shelved Amid Unfavorable Ruling	Apr. 15	MT
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm	Apr. 15	RE
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
BMO Raises Price Target on Eli Lilly to $900 From $865	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm EDT

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

746 USD

Average target price

813.3 USD

Spread / Average Target

+9.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B
SANOFI	-3.20%	113B

Other Pharmaceuticals

Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Eli Lilly and : to cut 250 jobs at France plant, through voluntary redundancy

Latest news about Eli Lilly and Company

Chart Eli Lilly and Company

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Eli Lilly and Company

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals